Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma

Frontiers in Oncology

Oncology

Junzhang Zhao¹  Long Xia²  Lei Zhang³  Wenguang Peng³  Weidong Pan³  Xiangjun Qian³  Jiarui Yang³  Jiancong Xie³  Hao Zhang³  Guojie Long³ 

[1] Department of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China;Department of Hepatobiliary-Pancreatic-Splenic Surgery, Inner Mongolia Autonomous Region People’s Hospital, Hohhot, China;Department of Pancreatic-Hepato-Biliary-Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China;

关键词: immunogenic cell death;    pancreatic ductal adenocarcinoma;    risk model;    prognosis;    tumor immune microenvironment;   

DOI  :  10.3389/fonc.2023.1178966

 received in 2023-03-03, accepted in 2023-03-16,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionImmunogenic cell death (ICD) is a sort of regulated cell death (RCD) sufficient to trigger an adaptive immunological response. According to the current findings, ICD has the capacity to alter the tumor immune microenvironment by generating danger signals or damage-associated molecular patterns (DAMPs), which may contribute in immunotherapy. It would be beneficial to develop ICD-related biomarkers that classify individuals depending on how well they respond to ICD immunotherapy.Methods and resultsWe used consensus clustering to identify two ICD-related groupings. The ICD-high subtype was associated with favorable clinical outcomes, significant immune cell infiltration, and powerful immune response signaling activity. In addition, we developed and validated an ICD-related prognostic model for PDAC survival based on the tumor immune microenvironment. We also collected clinical and pathological data from 48 patients with PDAC, and patients with high EIF2A expression had a poor prognosis. Finally, based on ICD signatures, we developed a novel PDAC categorization method. This categorization had significant clinical implications for determining prognosis and immunotherapy.ConclusionOur work emphasizes the connections between ICD subtype variations and alterations in the immune tumor microenvironment in PDAC. These findings may help the immune therapy-based therapies for patients with PDAC. We also created and validated an ICD-related prognostic signature, which had a substantial impact on estimating patients' overall survival times (OS).

【 授权许可】

Unknown   
Copyright © 2023 Peng, Yang, Xia, Qian, Long, Zhang, Xie, Zhao, Zhang and Pan